Findings

What do systematic reviews say?

1,788 questions · 1,849 findings · 336 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 245 · 13.3%GRADE not reported 126 · 6.8%Very low 612 · 33.1%Low 512 · 27.7%Moderate 305 · 16.5%High 49 · 2.7%

Epoetin theta vs epoetin beta

Final Hb · anaemia in predialysis patients

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 288 participants
Moderate

Epoetin theta vs epoetin beta

Mean weekly epoetin dose · anaemia in predialysis patients

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 288 participants
Low

Epoetin theta vs epoetin beta

Deaths · anaemia in predialysis patients

Epoetin theta showed no clear difference in deaths compared with epoetin beta (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 2.46 [0.29, 20.77]
1 study · 288 participants
Low

Epoetin theta vs epoetin beta

Adverse events: hypertension · anaemia in predialysis patients

Epoetin theta showed no clear difference in adverse events: hypertension compared with epoetin beta (moderate certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 0.35 [0.11, 1.08]
1 study · 288 participants
Moderate

Epoetin theta vs epoetin beta

Adverse events: RBC transfusions · anaemia in predialysis patients

Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.48 [0.06, 36.1]
1 study · 288 participants
Low

Epoetin theta vs epoetin beta

Withdrawals due to adverse events · anaemia in predialysis patients

Epoetin theta showed no clear difference in adverse events: discontinuation of therapy compared with epoetin beta (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.77 [0.68, 4.63]
1 study · 288 participants
Low

Epoetin alpha every 2 weeks vs to weekly

Number reaching target Hb · anaemia in predialysis patients

Epoetin alpha every 2 weeks may leads to lower number reaching target Hb compared with to weekly (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 0.96 [0.93, 0.99]
4 studies · 798 participants
Low

Epoetin alpha every 2 weeks vs to weekly

Number of deaths · anaemia in predialysis patients

Epoetin alpha every 2 weeks showed no clear difference in number of deaths compared with to weekly (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 0.89 [0.38, 2.07]
4 studies · 838 participants
Low

Epoetin alpha every 2 weeks vs to weekly

Adverse events: RBC transfusions · anaemia in predialysis patients

Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.56 [0.71, 3.45]
3 studies · 580 participants
Low

Epoetin alpha every 2 weeks vs to weekly

Adverse events: hypertension · anaemia in predialysis patients

Epoetin alpha every 2 weeks showed no clear difference in adverse events: hypertension compared with to weekly (moderate certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 0.85 [0.55, 1.32]
4 studies · 838 participants
Moderate

Epoetin alpha every 2 weeks vs to weekly

Adverse events: thrombovascular events · anaemia in predialysis patients

Epoetin alpha every 2 weeks showed no clear difference in adverse events: thrombovascular events compared with to weekly (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.41 [0.67, 3]
4 studies · 838 participants
Low

Epoetin alfa every four weeks vs with every two weeks

Change in Hb level · anaemia in predialysis patients

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 671 participants
Very low

Epoetin alfa every four weeks vs with every two weeks

Number reaching target Hb · anaemia in predialysis patients

It is very uncertain whether epoetin alfa every four weeks changes number reaching target Hb compared with with every two weeks (very low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 0.95 [0.84, 1.07]
3 studies · 687 participants
Very low

Epoetin alfa every four weeks vs with every two weeks

Number of deaths · anaemia in predialysis patients

Epoetin alfa every four weeks showed no clear difference in number of deaths compared with with every two weeks (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 0.95 [0.33, 2.75]
3 studies · 724 participants
Low

Vitamin A vs no supplementation

Neonatal mortality · promoting growth and development in very low birth weight infants receiving human milk

Supplemental vitamin A showed no clear difference in neonatal death compared with no supplementation (moderate certainty).

1 finding from 1 review

Vitamin A supplementation to prevent mortality and short‐ and long‐term morbidity in very low birth weight infants 2016 · Cochrane Headline outcomes only
RR 0.86 [0.66, 1.11]
6 studies · 1165 participants
Moderate

Vitamin A vs no supplementation

Chronic lung disease · promoting growth and development in very low birth weight infants receiving human milk

Supplemental vitamin A showed no clear difference in chronic lung disease (oxygen use at 28 days in survivors) compared with no supplementation (moderate certainty).

2 findings from 1 review

Vitamin A supplementation to prevent mortality and short‐ and long‐term morbidity in very low birth weight infants 2016 · Cochrane Headline outcomes only
RR 0.93 [0.86, 1.01]
7 studies · 1070 participants
Moderate
Vitamin A supplementation to prevent mortality and short‐ and long‐term morbidity in very low birth weight infants 2016 · Cochrane Headline outcomes only
RR 0.87 [0.77, 0.99]
5 studies · 986 participants
Moderate

Vitamin A vs no supplementation

Death or chronic lung disease · promoting growth and development in very low birth weight infants receiving human milk

Supplemental vitamin A probably leads to lower death or chronic lung disease (oxygen use at 28 days) compared with no supplementation (moderate certainty).

2 findings from 1 review

Vitamin A supplementation to prevent mortality and short‐ and long‐term morbidity in very low birth weight infants 2016 · Cochrane Headline outcomes only
RR 0.93 [0.88, 0.99]
6 studies · 1165 participants
Moderate
Vitamin A supplementation to prevent mortality and short‐ and long‐term morbidity in very low birth weight infants 2016 · Cochrane Headline outcomes only
RR 0.92 [0.84, 1.01]
4 studies · 1089 participants
Moderate

Vitamin A vs no supplementation

Death before 36 weeks' postmenstrual age · promoting growth and development in very low birth weight infants receiving human milk

Supplemental vitamin A showed no clear difference in death before 36 weeks' postmenstrual age compared with no supplementation (moderate certainty).

1 finding from 1 review

Vitamin A supplementation to prevent mortality and short‐ and long‐term morbidity in very low birth weight infants 2016 · Cochrane Headline outcomes only
RR 1 [0.77, 1.29]
4 studies · 1089 participants
Moderate

Vitamin A vs no supplementation

Neurodevelopmental impairment at 18 to 22 months · promoting growth and development in very low birth weight infants receiving human milk

Supplemental vitamin A showed no clear difference in neurodevelopmental impairment at 18 to 22 months compared with no supplementation (low certainty).

1 finding from 1 review

Vitamin A supplementation to prevent mortality and short‐ and long‐term morbidity in very low birth weight infants 2016 · Cochrane Headline outcomes only
RR 0.89 [0.74, 1.08]
1 study · 538 participants
Low

Tibolone vs placebo

Vasomotor symptoms (all doses) · postmenopausal women with vasomotor symptoms

Tibolone probably leads to lower vasomotor symptoms (all doses) compared with placebo (moderate certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.33 [0.27, 0.41]
5 studies · 842 participants
Moderate